Birth Defect Clinical Trials
A listing of Birth Defect medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 24 clinical trials
A PHASE II TRIAL OF EPIGENETIC PRIMING IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
The purpose of this study is to determine if epigenetic priming with DNA methyltransferase inhibitors (DMTi) prior to chemotherapy blocks is safe and effective in treating children with acute myeloid leukemia (AML).
- 0 views
- 19 Feb, 2024
- 1 location
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
This randomized phase III trial compares how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed).
- 0 views
- 19 Feb, 2024
- 1 location
An Open-label Multicenter Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and =30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
The purpose of this study is to see if Daratumumab is useful for treating pediatric (subjects aged >=1 to 18 years) and young adult patients (aged 18 to 30 years) with acute lymphoblastic leukemia or lymphoblastic lymphoma.
- 0 views
- 19 Feb, 2024
- 1 location
A Phase III International Randomized Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
The study's primary objective [in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)], is to compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R …
- 0 views
- 19 Feb, 2024
- 1 location
Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
The purpose of this Managed Access Program (MAP) Treatment Plan is to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release where no overwhelming safety concerns has been …
- 0 views
- 19 Feb, 2024
- 1 location
Phase I trial of azacitidine plus nivolumab following reduced-intensity allogeneic PBSC transplantation for patients with AML and high-risk myelodysplasia
The purpose of this study is to find the maximum safe dose of nivolumab alone, and of nivolumab combined with azacitidine after reduced-intensity allogeneic peripheral blood stem cell (PBSC) transplantation. Another purpose is to see how the study drugs affect different aspects of transplant such as infection and disease response.
- 0 views
- 19 Feb, 2024
- 1 location
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
This randomized phase III clinical trial compares how well combination chemotherapy works when given with or without bortezomib in treating patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma.
- 0 views
- 19 Feb, 2024
- 1 location
A Study to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
BAN2401 is an investigational study drug which is being studied in people who have early AD (Alzheimer's disease), with mild cognitive (thinking) impairment or mild dementia. People with AD have a build-up of abnormal protein known as amyloid in their brains. This build up may lead to impairment in memory …
- 0 views
- 19 Feb, 2024
- 1 location
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with CD22 positive B acute lymphoblastic leukemia that has come back or does not respond to treatment.
- 0 views
- 19 Feb, 2024
- 1 location
A Phase II Pilot Trial to Estimate Survival After a Non-total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed With B-acute Lymphoblastic Leukemia (ALL) Who Are Pre-allogeneic Hematopoietic Cell Transplantation (HCT) Next-generation-sequence (NGS) Minimal Residual Disease (MRD) Negative
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT).
- 0 views
- 19 Feb, 2024
- 1 location